98. Eosinophilic gastrointestinal disease Clinical trials / Disease details
Clinical trials : 172 / Drugs : 149 - (DrugBank : 39) / Drug target genes : 38 - Drug target pathways : 135
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT00635089 (ClinicalTrials.gov) | July 2008 | 6/3/2008 | Open-Label Extension Study of Reslizumab in Pediatric Subjects With Eosinophilic Esophagitis | An Open-Label Safety and Efficacy Study of Reslizumab (CTx55700) for the Treatment of Pediatric Subjects With Eosinophilic Esophagitis Who Completed Study Res-5-0002 | Eosinophilic Esophagitis | Drug: reslizumab | Ception Therapeutics | Cephalon | Completed | 5 Years | N/A | All | 190 | Phase 3 | United States;Canada |
| 2 | NCT00538434 (ClinicalTrials.gov) | March 2008 | 1/10/2007 | Efficacy and Safety Study of Reslizumab to Treat Eosinophilic Esophagitis in Subjects Aged 5 to 18 Years | An Efficacy and Safety Study of Reslizumab (CTx55700) in the Treatment of Eosinophilic Esophagitis in Subjects Aged 5 to 18 Years | Eosinophilic Esophagitis | Biological: Reslizumab;Other: Saline | Ception Therapeutics | NULL | Completed | 5 Years | 18 Years | All | 227 | Phase 2/Phase 3 | United States;Canada |